Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst Greg Harrison maintains a Sector Outperform rating on Agios Pharmaceuticals and raises the price target from $51 to $53.
November 01, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank has increased its price target for Agios Pharmaceuticals from $51 to $53, maintaining a Sector Outperform rating. This suggests confidence in the company's future performance.
The increase in price target and maintained outperform rating by Scotiabank indicates a positive outlook on Agios Pharmaceuticals' stock, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100